Dr. Alexander Andrianov Joins Apogee as Vice President of Research and Development

Apogee Technology, Inc. (AMEX: ATA), an emerging
micro-systems and nanotechnology company that designs, develops and
commercializes medical devices and sensor products, announced today
that Dr. Alexander Andrianov has joined Apogee as the Vice President
of Research and Development. Dr. Andrianov will support the design and
development of novel drug coating and encapsulation technologies for
the Company's PyraDerm(TM) intradermal drug delivery system.
   Dr. Andrianov brings over 20 years experience in applications of
polymers as biomaterials and drug delivery systems. Most recently he
was the founder Chief Scientific Officer of Parallel Solutions from
2001 until 2005, where he developed biodegradable polymers for protein
delivery and discovered a new class of potent vaccine immunoadjuvants.
Prior to starting Parallel, he worked for Physical Science, Inc. as
Principal Research Scientist and at Avant Immuonotherapeutics, Inc. as
Director of Polymer Synthesis and Formulation. Dr. Andrianov is listed
as an inventor on over 35 patents and patent applications and has
published numerous technical papers. Dr. Andrianov received his Ph.D.
in Polymer Science from Moscow State University in 1985 and served as
a faculty member until 1991. He continued his academic training at the
Massachusetts Institute of Technology working with Professor Robert
Langer.

   About Apogee Technology, Inc.

   Apogee Technology designs, develops and commercializes proprietary
medical device and sensor products using its MEMS and nanotechnology
for the medical, automotive, industrial and consumer markets. The
Company is developing its PyraDerm(TM) solution for enhanced
intradermal drug delivery and has introduced a family of pressure
sensors under the Sensilica(TM) brand. Apogee's goal is to provide
value-added and cost-savings solutions for our customers and, in so
doing, to become a global leader in the sensor and medical device
fields. For more information please visit our web site at:
http://www.apogeemems.com.

   PyraDerm(TM) and Sensilica(TM) are trademarks of Apogee
Technology, Inc. All other product names noted herein may be
trademarks of their respective holders. Certain statements made herein
that use the words "anticipate," "hope," "estimate," "project,"
"intend," "plan," "expect," "believe" and similar expressions are
intended to identify forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve known and unknown risks and
uncertainties, which could cause the actual results, performance or
achievements of the Company to be materially different from those that
may be expressed or implied. Please refer to the company's risk
factors as set forth in the Company's filings with the Securities and
Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.